Immunosequencing, the science of profiling T- and B-cell receptors, enables incredible insight into the immune system and its role in numerous disease states. This webinar will give a brief overview of Adaptive Biotechnologies’ immunoSEQ® Assay and delve into how immunosequencing data can and has been used to examine autoimmune diseases.
In this webinar, Dr. Boland and Dr. Raber will highlight autoimmune diseases and autoimmune-like states and present published studies using immunoSEQ Technology. Examples will include repertoire properties associated with autoimmunity, identifying antigen-specific clones, tracking clones over time and how repertoire and clone-level data can be integrated with clinical data to drive understanding and progress in the field. Additionally, the speakers will describe different ways to work with Adaptive Biotechnologies, including an upgraded human TCRB Kit to perform the gold-standard immunosequencing in your own lab, as well as collaboration opportunities to help build the TCR Antigen Map.
Katie Boland, DVM, PhD, Scientific Liaison, Adaptive Biotechnologies
Dr. Katie Boland is a veterinary pathologist and immunologist with 19 years of research experience and is an expert in the field of immunosequencing. Her current role at Adaptive Biotechnologies is leading a team of scientific liaisons and other scientific and technical support experts to help Adaptive’s academic customers incorporate immunosequencing into a broad range of research applications. Dr. Boland holds a PhD in Immunology from Washington State University where she focused on T cells in mucosal immunity and vaccine development, while concurrently completing a veterinary anatomic pathology residency. She also holds a Doctor of Veterinary Medicine from Michigan State University and a Bachelor of Arts in Biochemistry from Case Western Reserve University.Message Presenter
Patrick Raber, PhD, Research and Business Development Manager, Adaptive Biotechnologies
Dr. Patrick Raber is an immunologist with 12 years of research experience and is an expert in the field of immunosequencing. His current role at Adaptive Biotechnologies centers on the incorporation of immunosequencing into translational research and clinical trials for Adaptive’s academic research and biopharmaceutical partners with a focus on the key elements of experimental design, data analysis and data interpretation. Dr. Raber holds a PhD in Immunology from the LSU Health Sciences Center in New Orleans where he focused on T-cell suppression in the tumor microenvironment by MDSCs and methods to improve adaptive cellular immunotherapies. He also holds a Bachelor of Science in Microbiology from the University of Georgia.Message Presenter
Who Should Attend?
This webinar will appeal to senior professionals who are:
- Academic and pharma oncology researchers
- Biomarker researchers
immunoSEQ is Research Use Only.
Not for use in diagnostic procedures.
What You Will Learn
Webinar participants will gain insights into:
- Adaptive’s immunoSEQ technology for sequencing T-cell and B-cell receptors at high throughput has applications in autoimmune diseases such as Crohn’s disease, multiple sclerosis, psoriasis, narcolepsy and alopecia as well as treatment-induced autoimmunity
- How immuonsequencing can be used to understand autoimmune disease pathology, responses to different treatment modalities, and duration of treatment response
- Through its Antigen Map program, Adaptive wants to build better diagnostics for autoimmune diseases and is actively seeking collaborators with emphasis on digestive diseases and rheumatoid arthritis
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.